Company intelligence / Profile preview
Telormedix
Lugano-Bioggio, Switzerlandtelormedix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead product TMX-101 was in Phase II clinical trial for the treatment of CIS (carcinoma in situ) in the bladder as of 2013. TMX-302 was being developed for psoriasis treatment with EU funding.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Small moleculesImmunotherapeutic molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Research consortium with Biopta, Midatech Biogune, Molecular Profiles, and the University Hospital Zurich (USZ)
Beyond the preview
Go deeper on Telormedix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telormedix.